LXRX Lexicon Pharmaceuticals Inc.

5.51
+0.17  (+3%)
Previous Close 5.34
Open 5.36
Price To Book -19.68
Market Cap 583648965
Shares 105,925,402
Volume 578,120
Short Ratio
Av. Daily Volume 718,813

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiated September 2017.
Sotagliflozin
Type 2 Diabetes
Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
PDUFA date March 22, 2019. Advisory Committee Meeting January 17, 2019 voted 8-8 that benefits outweigh risks.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 data due 4Q 2019.
Sotagliflozin
Type 2 Diabetes
Phase 1a data released December 18, 2018. Favorable safety/tolerability profile. MAD trial to commence 1Q 2019.
LX9211
Neuropathic pain